Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its ...

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...